Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
about
Current Treatment Approaches to HCC with a Special Consideration to TransplantationLiving donor liver transplantation in the USAHepatocellular carcinoma: Where are we?Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patientsDiagnostic and therapeutic management of hepatocellular carcinomaLiver transplantation for hepatocellular carcinoma from living-donor vs. deceased donorOutcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort.Liver transplantation for malignancy: current treatment strategies and future perspectives.Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma.Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.Hong Kong consensus recommendations on the management of hepatocellular carcinoma.The International Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline.Deceased-donor split-liver transplantation in adult recipients: is the learning curve over?Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysisEvaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA-positive cancer-associated fibroblasts.Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis.Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.Treatment of hepatocellular carcinoma: a systematic review.Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.Current developments in pediatric liver transplantationRecurrence of hepatocellular carcinoma after liver transplantation: an update.Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population.Hepatic venous congestion in living donor grafts in liver transplantation: is there an effect on hepatocellular carcinoma recurrence?Living donor liver transplantation for hepatocellular carcinoma: through the looking glass.Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry.Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience.Surgical Treatment of Hepatocellular Carcinoma.Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations
P2860
Q26740375-B0825C56-26B6-4E39-81C5-84304CE3A216Q26749806-3EDEA2EC-1C39-4389-B127-8FF761BBFABFQ26765182-06B82EBE-A220-48C0-AF52-C493ED3D4ACBQ26766049-D8212794-4E98-4217-8D62-D58871BC1480Q26999043-CBD6FCE0-B64C-4487-B481-1F75DBD44B8EQ28073940-DD589EC2-AABF-4533-B421-96346F6BB089Q30416480-5D83A06F-2A83-476C-887C-57FC91EFD375Q33594868-C92363B3-B133-44E4-9E02-C5A96D31D388Q33872038-57B1505E-5F44-4862-99C9-1FCBDAF83D96Q34067940-11A596E8-3F9C-41B9-97F9-FBC35810B99DQ34263346-C7214D48-F079-4232-9B1C-29C7504EFFEDQ35384660-DE362906-F877-4F19-A487-EBC45F7D58F1Q35631295-3DEBFEF7-6C3B-4B3D-B902-6990206D4FFCQ36355049-FAB9EC7D-E311-4291-AAB3-C2CAFE7C972CQ36926615-C2DF2883-BAA1-4927-BD09-83E62D653610Q37203571-5C69349E-882D-4D9B-9502-FCAE6E4392A3Q37260604-C4234BCA-6D92-435C-A035-A5B9BE69D241Q37708048-BE853836-E073-4A7D-8665-38BDF592E316Q38060208-77FB7B75-5BA7-4C5B-B311-6AC57F7F90D8Q38073121-362071FD-BF47-4F5E-87E8-8F71D56BB86CQ38155508-8D48FE4E-1141-4765-AE18-7351117FBFBAQ38406220-5D58F835-D320-4253-A1EA-05F84727184CQ38530791-DB9C61B6-9A6C-4405-AF5C-2F8F580C8CCBQ38594469-6BCE6E5D-B7BD-42D2-BD6E-F5C42A20E7E6Q41002670-24F141B4-2883-4802-9632-90B9931216CAQ44606962-7CE18C8B-817B-4E97-82DD-484957421036Q44734515-B81976FB-BA49-4627-9E32-F5786416B4D7Q48372554-BF225520-F338-41F2-A718-7527FCBD3BD4Q49151614-C9A7E699-AFD3-4AEF-AF86-34A15A05B4F4Q54989355-7C724592-4BF0-4F69-BA6E-1BEB40EB9727Q58021206-43B8622B-6CBC-4B5C-AE8C-AF9F2C340B2A
P2860
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Living donor liver transplanta ...... rable survival and recurrence.
@en
Living donor liver transplanta ...... rable survival and recurrence.
@nl
type
label
Living donor liver transplanta ...... rable survival and recurrence.
@en
Living donor liver transplanta ...... rable survival and recurrence.
@nl
prefLabel
Living donor liver transplanta ...... rable survival and recurrence.
@en
Living donor liver transplanta ...... rable survival and recurrence.
@nl
P2093
P2860
P356
P1476
Living donor liver transplanta ...... arable survival and recurrence
@en
P2093
Anand Ghanekar
Charbel Sandroussi
David R Grant
Eberhard L Renner
Lakhbir Sandhu
Mark S Cattral
Markus Guba
Markus Selzner
Paul D Greig
P2860
P304
P356
10.1002/LT.22477
P577
2012-03-01T00:00:00Z